Direct oral anticoagulants versus warfarin for the treatment of inferior vena cava thrombus.
direct oral anticoagulant
inferior vena cava thrombus
vitamin K antagonist
warfarin
Journal
European journal of haematology
ISSN: 1600-0609
Titre abrégé: Eur J Haematol
Pays: England
ID NLM: 8703985
Informations de publication
Date de publication:
Dec 2023
Dec 2023
Historique:
revised:
24
08
2023
received:
30
06
2023
accepted:
24
08
2023
medline:
9
11
2023
pubmed:
9
9
2023
entrez:
9
9
2023
Statut:
ppublish
Résumé
To evaluate the efficacy and safety of direct oral anticoagulants (DOACs) compared to warfarin in patients with inferior vena cava (IVC) thrombus. This was a single-system, retrospective cohort study of hospitalized adult patients with IVC thrombus treated with a DOAC or warfarin therapy. The primary efficacy endpoint was the thrombus resolution on imaging, and the primary safety endpoint was major bleeding, both assessed within 6 months of hospital discharge. Secondary endpoints included hospitalization for a bleeding-related event, pulmonary embolism, or death within 6 months of hospital discharge. A total of 33 patients were included in the study. Twenty-three (70%) patients received a DOAC, and 10 (30%) received warfarin. Of the 10 patients with repeat imaging available, complete resolution was noted in two (33%) DOAC patients and no warfarin patients (p = .5). Major bleeding occurred in two (8.7%) DOAC patients and one (10%) warfarin patient (p = .9). No significant differences in secondary endpoints were observed between groups. There were no differences in efficacy and safety between patients receiving DOACs or warfarin for the treatment of IVC thrombus, although results are limited by the small patient population and number of patients with repeat imaging available.
Substances chimiques
Warfarin
5Q7ZVV76EI
Anticoagulants
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
909-913Informations de copyright
© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
Références
Alkhouli M, Morad M, Narins CR, Raza F, Bashir R. Inferior vena cava thrombosis. JACC Cardiovasc Interv. 2016;9(7):629-643.
McAree BJ, O'Donnell ME, Fitzmaurice GJ, Reid JA, Spence RAJ, Lee B. Inferior vena cava thrombosis: a review of current practice. Vasc Med. 2013;18(1):32-43.
Kearon C, Akl EA, Ornelas J, et al. Antithrombotic therapy for VTE disease. Chest. 2016;149(2):315-352.
Ortel TL, Neumann I, Ageno W, et al. American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism. Blood Adv. 2020;4(19):4693-4738.
Teter K, Schrem E, Ranganath N, et al. Presentation and management of inferior vena cava thrombosis. Ann Vasc Surg. 2019;56:17-23.
Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342-2352.
The EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499-2510.
Agnelli G, Buller HR, Cohen A, et al. Oral Apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799-808.
The Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(1415):1406-1415.
Kido K, Noyes E, Gutnik L. Successful use of rivaroxaban in inferior vena cava thrombosis provoked by multiple traumatic injuries and surgeries: a case report. J Clin Pharm Ther. 2017;42(5):631-633.
Imanishi J, Iseri M, Motoki M, et al. An unusual case of inferior vena cava thrombosis in a healthy male bodybuilder. Intern med. 2018;57(17):2517-2521.
Sakatani A, Nishio M, Kume K, Doi Y, Hirooka K. Rivaroxaban for fully occlusive inferior vena cava filter thrombus. Circ J. 2019;83(7):1616.
Du J, Nie M, Yan Z, Fu J, Sun J, Liu F. Safety and efficacy of rivaroxaban for inferior vena cava thrombosis after successful catheter-directed thrombolysis. Semin Thromb Hemost. 2022;48(4):459-464.
Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692-694.